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Abstract
We assessed the cardiovascular safety of long-term direct-acting oral anticoagulant (DOAC) treatment. A search of the medical
literature was performed from inception until May 31, 2019. Inclusion criteria were (1) randomized trial that assessed the clinical
efficacy and/or safety of 1 or more DOAC, (2) control group including oral anticoagulation and/or antiplatelet and/or placebo
treatment, and (3) the incidence of acute coronary syndrome during follow-up was reported. Fixed-effect and random-effects
models were applied. The analyzed outcomes were myocardial infarction (MI), major bleeding, and mortality. Twenty-eight
randomized clinical trials (196 761 patients) were included. Rivaroxaban was associated with a 21% reduction in the relative
risk of MI when compared to placebo (relative risk [RR]: 0.79 [95% credible interval, CrI: 0.65-0.94]) and a 31% reduction (RR:
0.70 [95% CrI: 0.53-0.89]) when compared to dabigatran. Apixaban resulted in 24% (RR: 0.76 [95% CrI: 0.58-0.99]) and vitamin K
antagonists anticoagulation resulted in 19% (RR: 0.81 [95% CrI: 0.65-0.98]) risk reduction compared to dabigatran. The computed
probability of being the first best choice of treatment was 61.8% for rivaroxaban. Cardiovascular safety shows considerable
heterogeneity among oral anticoagulants. Treatment with rivaroxaban is associated with reduced rate of MI.
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Introduction
Ten years have passed since the approval of the first non-
vitamin K antagonist oral anticoagulants. Direct oral anticoa-
gulants (DOACs) have been proposed as an alternative term for
this class of agents including oral direct thrombin inhibitors
(DTIs) and activated factor X inhibitors (anti-Xa).1 In several
fields, compared to vitamin K antagonists (VKA), DOACs have
been proven to have similar or higher efficacy in preventing
ischemic events and similar or lower risk for major bleeding,
bleeding-related case fatalities, and intracranial bleeding.2,3
Furthermore, DOACs alleviate several problems associated
with VKA use including the need for laboratory monitoring due
to the narrow therapeutic window and drug/food interactions. 4
Consequently, DOACs have been widely adopted.5
Coronary heart disease (CHD) is the leading cause of death
and disability having a major impact on both developing and
developed nations.6 The coagulation cascade plays an impor-
tant role in the evolution of acute coronary syndrome (ACS)
events.7 Earlier analyses found that long-term treatment with
VKAs, in monotherapy or in combination with aspirin, is
superior to aspirin alone for secondary prevention after acute
myocardial infarction (MI).8
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Importantly, DOACs showed dissimilar results regarding
cardiovascular (CV) safety. Rivaroxaban showed favorable
outcomes when combined with aspirin among patients with
stable atherosclerotic disease, and it also reduced ischemic risk
in ACS.9,10 In contrast, signals from earlier studies have raised
safety concerns regarding MI risk among dabigatran-treated
patients, but dabigatran lowered the risk of major vascular
complications among patients with myocardial injury after
surgery.11,12
Direct comparative trials are not available to compare the
risk of MI among DOAC-treated patients. Therefore, we per-
formed a Bayesian multiple treatment network meta-analysis
(NMA) of randomized clinical trials in order to summarize the
data of DOAC trials and gain insight into CV safety.
Methods
A manual search of medical literature was performed in
PubMed (MEDLINE), EMBASE, and Cochrane Trials from
inception until May 31, 2019, for articles reporting randomized
clinical trials with DOACs. No language restriction was used.
The query included the following terms linked with Boolean
operators: “pulmonary embolism,” “atrial fibrillation,”
“thromboprophylaxis,” “anticoagulation,” “prevention,”
“rivaroxaban OR apixaban OR dabigatran OR edoxaban” (for
detailed search history, refer to the Online Appendix).
In the analysis, we included trials that fulfilled the following
criteria: (1) randomized clinical trials (RCTs) that assessed the
clinical efficacy and/or safety of an anticoagulant protocol
comprising either 1 of the approved and marketed DOACs,
that is, dabigatran, rivaroxaban, apixaban, or edoxaban. (2)
Having one or more control group with oral anticoagulation,
antiplatelet treatment, or placebo. (3) Reporting the frequency
of MI or the rate of ACS during the follow-up compliant with
intention-to-treat analysis. Studies that aimed to compare
merely the biological efficacy of the anticoagulant protocol
and trials not reporting the frequency of MI were excluded.
Nonrandomized studies, registries, and uncontrolled or cohort
studies as well as reviews were disregarded. The review pro-
tocol was registered in the PROSPERO database a priori under
the registration number of CRD42018103000.
All the relevant articles were combined in a reference man-
ager software (EndNote X8; Clarivate Analytics, Philadelphia,
PI) to remove duplicates by searching overlaps between titles,
abstracts, authors, and publication year. After removing dupli-
cates, we screened the articles by title, abstract, and full texts
against our predefined eligibility criteria. Each phase was
carried out by 2 independent investigators (P.K. and Z.S.) in
duplicate, none of whom were blinded to publication data.
Third-party (A.K.) arbitration resolved any discrepancies.
The following details were recorded for each study: study
name, first author, year of publication, period of study, the
applied doses of oral anticoagulant, number of patients, length
of treatment period, length of follow-up, inclusion and exclu-
sion criteria, protocol definitions of MI as well as patient and
procedural characteristics including mean age, sex, and the
following risk factors: diabetes, hypercholesterolemia, and
hypertension.
The primary end point of the analysis was the frequency of
MI. Overall mortality was defined as a secondary end point. As
a safety measure, frequency of major bleeding complications
was evaluated. Both MI and major bleeding were defined
according to the internal definitions of the studies. If multiple
major bleeding definitions were used, we extracted thrombo-
lysis in myocardial infarction (TIMI) major bleeding and Inter-
national Society on Thrombosis and Hemostasis major
bleeding if available (Table 1). The data from intention to treat
analyses were extracted. The end points of interest were col-
lected until the longest follow-up available.
Analyses of subgroups, heterogeneity, as well as assessment
of bias were performed using the Cochrane Review Manager
version 5.3. software.15 Degree of inconsistency among studies
was quantified by means of I2. Cochrane Q heterogeneity test
(w2) was also performed. These data were reported as percent-
age of the I2 together with the P value of the w2 test. The
likelihood of publication bias was visually assessed by gener-
ating a funnel plot for the primary end point. The risk of MI was
analyzed in a hierarchical Bayesian mixed-treatment compari-
son meta-analysis. The Bayesian analysis allows the combina-
tion of existing knowledge with new information according to
established rules of probability.16 Substantive prior knowledge
can thereby be included in any Bayesian analysis by choice of
initial (predata) distribution. We wanted our final (posterior)
distribution to reflect the information in our data set only and
not to be influenced by our choice of initial (prior) distribution.
Therefore, “noninformative” prior distributions were used
throughout so that the data from the trials dominated the final
inferences. The RCT data were then added via the Bayes rule to
produce posterior distributions. Treatment effects are reported
as risk ratio with 95% associated credible interval (CrI), which
is a Bayesian analog of the 95% confidence interval from tra-
ditional meta-analyses. Inferences were calculated with a
Gibbs sampler algorithm as implemented through WinBUGS
software (version 1.4.3; MRC Biostatistics Unit, Cambridge,
United Kingdom).17 To ensure convergence, 3 Markov Monte
Carlo chains were run. Data input and graphical output were
performed using the NetMetaXL interface.18 Inferences based
on random effects models are presented. The choice of
random-effects model was made based on the consideration
that the true preventive effect of anticoagulant treatment may
vary from study to study influenced by heterogeneity of the
included trials. Random-effects model accounts better for
interstudy differences; furthermore, it results in wider cred-
ible intervals and thus provides more conservative and robust
results. To supplement the information of random-effects
modeling, fixed-effects models were also built and analyzed
as sensitivity test. Subgroup analyses were performed by
building networks of studies performed in the same risk
groups as well as according to MI definitions (see Online
Appendix). Meta-regression analyses were performed using
the Open Meta-analyst software (Brown University, RI).19
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Results
Twenty-eight RCTs involving 196 761 (range: 1280-27 395)
patients were analyzed (Figure 1). The main characteristics of
these trials are shown in Table 1. Clinical characteristics of the
included populations and procedural data of the trials are
reported in Supplementary Table 1. Patients were recruited to
the trials due to nonvalvular atrial fibrillation,20-27 including
those scheduled for elective cardioversion,28-30 patients after
embolic stroke of undetermined source,31,32 patients treated for
pulmonary embolism or deep vein thrombosis,33-40 as well as
cases at high risk for CHD10,41,42 including ACS. According to
the applied anticoagulants, study arms were grouped into 8
groups. The geometry of the network is depicted in Figure
2A. Dose of the anticoagulant was different and as follows:
150 mg twice daily and 110 mg twice daily for dabigatran, 5
mg once daily to 10 mg twice daily for apixaban, 30 mg once
Figure 1. PRISMA flow diagram of the systematic review and source selection.
Figure 2. Study network, myocardial infarction frequencies, and ranking. A, Plot of the study network. Nodes show anticoagulation treatments
being compared, and edges represent an available direct comparison between pairs of intervention. B, Rate of myocardial infarction according to
the treatment groups. Whiskers depict minimal and maximal rates. The diamond depicts the aggregate rate, and its size is proportional to the
number of patients treated with the particular intervention. C, Clustered ranking plot of the network. The plot is based on the cluster analysis of
SUCRA curves, and the plot shows SUCRA values for the risk of myocardial infarction and mortality. Size of the circles is plotted based on the
SUCRA values for major bleeding. AP indicates placebo; D, dabigatran; R, rivaroxaban; E, edoxaban; A, apixaban; W, warfarin; ASA, aspirin; Rv,
rivaroxaban vascular dose; SUCRA, surface under the cumulative ranking.
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daily and 60 mg once daily for edoxaban, while rivaroxaban
dose ranged from 10 mg daily (once daily or twice daily) up to
30 mg daily except for 4 studies testing “rivaroxaban vascular”
2.5 mg twice-daily doses.9,10,24,41 Control treatment arm was
aspirin in 5, VKA in 18, and placebo in 5 trials. Study defini-
tions of MI were discrepant (Table 1).13,14
Low-dose (100/165 mg daily) aspirin treatment was
allowed in all studies. Combined antiplatelet therapy was
allowed in 13 studies.9,12,41,42,43,23-27,29,36,40 Analysis of bias
showed high quality of the source information with low prob-
ability of possible bias. No obvious publication bias was found
(Supplemental Figures 1 and 2).
In the included trials, 3554 MIs occurred in the VKA arm
with lowest rate (1.25%) and in the placebo arms with the
highest rate (4.55%; Figure 2B). Heterogeneity analysis
showed consistent results within treatment groups (dabigatran
I2: 26%, w2: P ¼ .23 and I2: 0%, w2: P  .53 for all other
DOACs), while high heterogeneity was seen among DOAC
subgroups (I2: 64.2%, w2: P ¼ .02; Supplemental Figure 1).
Exclusion of the Secondary Prevention of Venous Thrombo
Embolism (RE-MEDY) or the Management of Myocardial
Injury After Noncardiac Surgery (MANAGE) trial but none
of the others corrected the I2 value in the dabigatran subgroup
to zero (data not shown).
Rivaroxaban was associated with a relative risk (RR) reduc-
tion of 21% regarding MI when compared to placebo (RR: 0.79
[95% CrI: 0.65-0.94]) and a 31% reduction (RR: 0.70 [95%
CrI: 0.53-0.89]) when compared to dabigatran. Apixaban
resulted in 24% (RR: 0.76 [95% CrI: 0.58-0.99], and VKA
resulted in 19% (RR: 0.81 [95% CrI: 0.65-0.98]) risk reduction
compared with dabigatran. Furthermore, rivaroxaban in vascu-
lar dose resulted in 16% (RR: 0.70 [95% CrI: 0.70-0.99])
reduction compared with placebo, as well as 27% (RR 0.80
[95% CrI: 0.56-0.96] risk reduction compared to dabigatran
(Table 2, Figure 3).
Leave-one-out analysis disregarding the data from the Ran-
domized Evaluation of Long Term Anticoagulant Therapy with
Dabigatran Etexilate (RE-LY) trial showed similar relations
with lower MI risk with rivaroxaban than with placebo (0.78
[0.64-0.94]) and dabigatran as well (RR: 0.66 [0.49-0.89]; Sup-
plemental Table 4).
The computed probability of being the first best choice of
treatment was 61.8% for rivaroxaban, 17.4% for very low-dose
rivaroxaban (5 mg daily), 14.2% for apixaban, 2.4% for VKAs,
3.0% for edoxaban, 1.1% for aspirin, and <0.1% for placebo
and dabigatran in the network.
Ranking remainedunaffected if data from theRE-LY trialwere
censored from the analysis. Ranking based onmortality andmajor
bleeding result showed trends of similar ranks with MI and mor-
tality, while trends of major bleeding showed opposite tendencies
with lower ranking of bleeding at treatments with higher rankings
in MI (Figure 2C). However, neither of these trends were signif-
icant at regression analyses of the surface under the cumulative
ranking area values (R2 forMI andmortality: 0.035,P¼ .6577and
R2 for MI and major bleeding: 0.2963, P ¼ .1630).
In univariate meta-regression analyses, the rate of MI
showed positive association with the background risk and to
the rate of antiplatelet use but not to the treatment duration. In
Table 2. Indirect Comparisons of Different Oral Anticoagulants in a Network Meta-Analysis.a
Rivaroxaban Treatment 1
0.94 (0.76-1.15) 
1.22 (1.04-1.45)b
1.82 (0.79-2.17) 
Rivaroxaban 
vascular 
Myocardial 
infarcon 
Mortality 
Major bleeding 
Treatment 2 
0.90 (0.68-1.18) 
1.03 (0.87-1.25) 
1.72 (0.97-3.13) 
0.95 (0.70-1.29) 
0.85 (0.69-1.07) 
1.35 (0.66-2.70) 
Apixaban
0.88 (0.70-1.12) 
0.92 (0.79-1.07) 
0.90 (0.62-1.33) 
0.93 (0.72-1.25) 
0.75 (0.61-0.92)b
0.71 (0.39-1.22) 
0.98 (0.76-1.31) 
0.88 (0.76-1.02) 
0.52 (0.31-0.88)b
VKA
0.81 (0.61-1.01) 
0.96 (0.82-1.14) 
2.08 (0.23-3.57) 
0.86 (0.64-1.09) 
0.79 (0.66-0.95)b
1.61 (0.85-3.03) 
0.90 (0.64-1.23) 
0.93 (0.76-1.13) 
1.21 (0.63-2.27) 
0.92 (0.64-1.23) 
1.05 (0.86-1.28) 
2.27 (1.28-4.16)b
Aspirin
0.79 (0.55-1.13) 
1.00 (0.81-1.25) 
1.28 (0.64-2.63) 
0.84 (0.57-1.24) 
0.82 (0.64-1.06) 
1.00 (0.43-2.22) 
0.88 (0.60-1.30) 
0.97 (0.77-1.19) 
0.74 (0.34-1.62) 
0.90 (0.67-1.17) 
1.01 (0.93-1.27) 
1.41 (0.79-2.56) 
0.97 (0.66-1.53) 
1.04 (0.81-1.33) 
0.62 (0.27-1.42) 
Edoxaban
0.79 (0.65-0.94)b
0.96 (0.79-1.16) 
2.77 (1.54-5.00)b
0.84 (0.70-0.99) b
0.78 (0.63-0.97)b
2.13 (1.08-4.17)b
0.87 (0.67-1.11) 
0.92 (0.75-1.12) 
1.59 (0.84-3.03) 
0.89 (0.66-1.14) 
1.04 (0.86-1.27) 
3.03 (1.75-6.67)b
0.97 (0.72-1.33) 
0.99 (0.79-1.24) 
1.33 (0.64-2.70) 
1.00 (0.66-1.44) 
0.96 (0.75-1.22) 
2.13 (0.95-4.76) 
Placebo
0.70 (0.53-0.89)b
1.00 (0.82-1.21) 
1.72 (1.05-2.94)b
0.80 (0.56-0.96) b
0.82 (0.65-1.03) 
1.35 (0.71-2.56) 
0.76 (0.58-0.99) b
0.96 (0.78-1.16) 
1.01 (0.55-1.89) 
0.81 (0.65-0.98)b
1.09 (0.94-1.23) 
1.92 (1.32-2.86)b
0.87 (0.61-1.28) 
1.03 (0.82-1.30) 
0.84 (0.43-1.67) 
0.89 (0.61-1.27) 
1.00 (0.81-1.22) 
1.35 (0.68-2.77) 
0.90 (0.66-1.23) 
1.04 (0.85-1.28) 
0.63 (0.37-1.10) 
Dabigatran 
Abbreviation: VKA: vitamin K antagonist.
aLeague table shows the risk ratios (RR) and the 95% credible interval (CrI) of the different oral anticoagulants in a random effect model with vague prior for
myocardial infarction (first line), mortality (second line), and major bleeding (third line). RR < 1 means that the top left treatment (Treatment 1) is better.
bThe comparisons where the CrI did not overlap the line of equivalence.
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multiple analysis background risk, prevailed as a significant
determinant of the MI frequency (P ¼ .871 for antiplatelet and
P < .001 for the background risk). However, analyses of the RR
against aspirin showed no association either with the antiplate-
let use or with the background risk (Figure 4).
Discussion
In this meta-analysis involving 196 761 patients, we found
evidence that the choice of anticoagulant influences the risk
of MI in anticoagulated patients. When risk of MI is taken into
consideration, the probability of being the best choice of treat-
ment is the highest for rivaroxaban administered in antithrom-
botic or vascular prevention dose regimen, while the lowest is
for VKAs and the direct thrombin inhibitor, dabigatran.
Coagulation plays pivotal role in the development of CV
events; thus, CV safety of these drugs is of paramount interest.
Earlier analyses found favorable results for VKAs in the preven-
tion after acute MI.8 However, frequent bleeding complications
and the narrow therapeutic window with the need for careful
monitoring, in addition to drug and food interactions, limit the
benefits.44 In recent years, VKAs are progressively replaced by
the specifically acting oral anticoagulants (DOACs) offering an
easier and potentially safer option leading to a high number of
patients exposed to these drugs. Moreover, improving safety and
convenience of use raised the question as to whether DOACs
reopen the field of CV prevention for anticoagulation.
Several recent trials supported this concept including the
Anti-Xa Therapy to Lower Cardiovascular Events in Addition
to Standard Therapy in Subjects with Acute Coronary
Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS
ACS 2–TIMI 51) trial, where 2.5 mg rivaroxaban twice daily
improved the CV outcomes compared to placebo. Despite the
higher risk of bleeding, compared to placebo vascular dose
rivaroxaban reduced the rate of death of CV origin (2.7% vs
4.1%, P ¼ .002) and all other causes (2.9% vs 4.5%,
P ¼ .002).9 More recently in the Cardiovascular Outcomes for
People Using Anticoagulation Strategies (COMPASS) trial,
low-dose rivaroxaban combined with aspirin was associated
with a reduced risk of ischemic events and mortality among
patients with established, stable atherosclerotic disease, com-
pared to those receiving aspirin monotherapy. Although
Figure 3. Forest plot of the relative risk of myocardial infarction. A, B, and C, The relation of the myocardial infarction risk of the DOAC
treatments compared to the placebo and aspirin of vitamin K antagonist controls, respectively. D, Comparisons among the different DOAC
groups. DOAC indicates direct oral anticoagulant; VKA, vitamin K antagonists.
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bleeding complications were also more common, the combined
treatment with low-dose rivaroxaban resulted in superior net
clinical benefit.10 Furthermore, in the MANAGE trial among
patients with myocardial injury after noncardiac surgery,
twice-daily 110 mg dabigatran was tested against placebo and
resulted in fewer major vascular events, while bleeding com-
plications were similar in frequency (P ¼ .0115 and P ¼ .76,
respectively).12
Contrasting these recent results, there has been some ques-
tion ever since the publication of one of the earliest DOAC
phase 3 study, the RE-LY trial.26 In this trial, 2 doses of dabi-
gatran were shown to be either more effective in preventing
stroke with a similar bleeding risk or safer than warfarin with
similar prevention efficacy. Importantly, this study reflected
that patients receiving anticoagulant treatment for atrial fibril-
lation remain at risk of MI and found an excessive risk of MI
with dabigatran. There were numerically more MIs with both
doses of dabigatran than with warfarin, and the difference
reached statistical significance regarding the higher, 150 mg
dose. However, a subsequent post hoc analysis revealed addi-
tional events of stroke, bleeding, andMI, and the revised results
no longer showed a significant difference in MI.45
In the paucity of direct comparison randomized trials, sev-
eral studies including prospective and retrospective registries
attempted verification and characterization of the magnitude
of the potential MI risk of dabigatran-treated patients. These
studies, though subjected to several methodological short-
comings, especially an uncontrollable selection bias, could
neither reliably support nor refute the importance of this sig-
nal.46-48 Our extended review including a broad range of stud-
ies found that the data of randomized trials show important
differences favoring the Xa inhibitor rivaroxaban and
apixaban over dabigatran. This extends the earlier observa-
tions supporting that signal persists even after exclusion of the
RE-LY data and reaches beyond the field of patients with
atrial fibrillation.
Since the 2012 version of the European Society of Cardiol-
ogy CV disease prevention guideline, the concept of primary
and secondary prevention has been discouraged and replaced
by the recognition that atherosclerosis is a continuous pro-
cess.49 The results of our analysis are consistent with the large
body of evidence documenting the ability of anticoagulants to
reduce ischemic events in patients with or without established
CHD, including ACS.
Our analysis assessed the preventive potential of DOACs
from 2 approaches. First, the inclusion of 5 placebo and 5
aspirin-controlled trials enables to relate this potential to
established preventive therapy. Second, we found that the
differences in the rate of MI in the study arms were explain-
able by the background risk of the included study popula-
tions rather than by the differences in the rate of antiplatelet
treatment. The relative risks of the anticoagulant treatments
compared to aspirin were independent from both the rate of
antiplatelet treatment and background risk. Importantly, the
subgroup analyses according to the clinical indications or
the treatment length did not show a major influence on the
results. These findings suggest that the preventive potential
of DOACs is heterogeneous, correlates with that of aspirin
and VKA, and is independent of the concomitant antiplate-
let treatment.
The risk of MI with DOAC treatment has been assessed in
earlier systematic reviews and meta-analyses. Besides that,
these analyses did not include the results of some pivotal recent
trials including the COMPASS, MANAGE, and AUGUSTUS
Figure 4.Meta-regression analyses. In univariate meta-regression analyses, the rate of myocardial infarction (MI) showed positive regression to
the rate of antiplatelet use as well as to the background risk (A and B). Analyses of the risk ratio against aspirin showed no regression either to
the antiplatelet use or to the background risk (C and D).
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studies; they share some common limitations. These comprise
inclusion of underpowered, dose-finding, phase 2 trials.50-53
Only a few of them included trials with the recently approved
edoxaban53-55 but included trials with drugs that stopped devel-
opment.50,51,54,55 Some previous works restricted the analysis
to trials related only to atrial fibrillation and or deep vein
thrombosis/pulmonary embolism.53-55 Some based their
assumptions on the less robust fixed effect model that accounts
for interstudy heterogeneity less adequately.52,53
Some limitations of our analysis should be discussed. The
paucity of randomized trials comparing different DOAC agents
was one of the main reasons for the choice of this analysis but
represents also a limitation as the presented statistical infer-
ences rely substantially on indirect comparisons. It is improb-
able that a specific trial with MI as an end point and aiming to
perform a direct comparison of oral anticoagulants will ever be
conducted; thus, analysis of the available data set remains the
only option to shed light on these relationships.
Furthermore, safety and efficacy profiles of the anticoagu-
lants may be dose dependent, and the variability in drug regi-
mens might be a source of distortion. In fact, in trials testing
>1 dose of DOACs, the rate of MI was different in some
cases but similar in others. For example, 2.4% and 1.89%
with 30 and 60 mg once-daily edoxaban in the Global Study
to Assess the Safety and Effectiveness of Edoxaban vs Stan-
dard Practice of Dosing With Warfarin in Patients With
Atrial Fibrillation (ENGAGE AF—TIMI 48) trial, or 1.46%
and 1.43% with 110 or 150 mg twice-daily dabigatran in the
RE-LY trial among patients with AF, respectively.21 How-
ever, in most of the remaining trials, the rather complicated
schemes do not permit the study of dose–effect relationships.
Thus, we decided to form our analysis groups based on
DOAC exposure, with one exception regarding the distinc-
tion of the very low-dose rivaroxaban. Earlier studies with
warfarin show that ischemic protection requires to reach a
threshold of anticoagulation; above this limit, the rate of
bleeding complications but not necessarily the preventive
potential increases.56 Acknowledging that this relation may
apply to other means of anticoagulation, we handled
“vascular dose” rivaroxaban as distinct treatment groups.
Regarding VKA treatment, all but 3 included trials used war-
farin in their VKA arms. In 3 trials, acenocoumarol was also
allowed (see Table 1). Acknowledging that differences may
exist in CV safety of the different VKAs due to the paucity of
specific data, we could not differentiate among them.
Furthermore, definition of MI slightly differed across studies,
and none of them included trials had MI as an end point.
Moreover, there are >1 publication regarding the rates of
MI in the RE-LY trial.26,45 This shows that even with meti-
culously conducted trials, the capture and adjudication of
events may be incomplete. As data in the first publication
reflected the results of the prospective event adjudication
instead of a post hoc analysis, we used these in our analy-
ses.26 Furthermore, we performed sensitivity analyses that
did not show important influence on the result.
Conclusions
Our comprehensive meta-analysis involving 28 RCTs and 196
761 patients has identified significant differences in CV safety
among oral anticoagulants. Risk of MI is lowest with rivarox-
aban, followed by apixaban and edoxaban, while it is the high-
est for VKA and dabigatran. Differences in risk of MI may
influence the choice of treatment and may be considered in the
development of personalized antithrombotic regimens.
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